Axonics Inc
NASDAQ:AXNX

Watchlist Manager
Axonics Inc Logo
Axonics Inc
NASDAQ:AXNX
Watchlist
Price: 70.98 USD 0.75% Market Closed
Market Cap: 3.6B USD
Have any thoughts about
Axonics Inc?
Write Note

Axonics Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Axonics Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Axonics Inc
NASDAQ:AXNX
Depreciation & Amortization
-$9m
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Depreciation & Amortization
-$840m
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
-7%
Stryker Corp
NYSE:SYK
Depreciation & Amortization
-$616m
CAGR 3-Years
-1%
CAGR 5-Years
-7%
CAGR 10-Years
-13%
Abbott Laboratories
NYSE:ABT
Depreciation & Amortization
-$1.9B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
-13%
Intuitive Surgical Inc
NASDAQ:ISRG
Depreciation & Amortization
-$3m
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Axonics Inc
Glance View

Market Cap
3.6B USD
Industry
Health Care
Economic Moat
Narrow

Axonics Inc., a prominent player in the medical technology landscape, has carved a niche for itself by focusing diligently on the development and commercialization of innovative solutions for bladder and bowel dysfunction. Founded in 2012, the company's primary product is its Sacral Neuromodulation (SNM) system, designed to treat urinary and fecal incontinence. What differentiates Axonics is its dedication to addressing a pervasive issue with an underpinning focus on patient-centric design and effective long-term treatment. Its SNM system offers users rechargeable batteries, providing a less invasive and more cost-effective solution compared to traditional systems. This technology not only addresses significant medical needs but also aligns well with a growing trend toward minimally invasive solutions in medtech. The operational model of Axonics is straightforward yet well-suited to drive profitability. Revenues primarily derive from the sales of its SNM system, which is marketed directly to healthcare providers and practitioners. This involves an intricate network of sales representatives and a hands-on approach to training medical professionals on the benefits and use of their systems, ensuring that the technology translates efficiently into patient treatment. By focusing extensively on a specific segment within the broader medical device industry, Axonics has positioned itself to capitalize on a substantial market opportunity, driven by an aging population and increasing rates of incontinence-related conditions. This strategic approach not only underscores its commitment to delivering effective healthcare solutions but also signifies its potential for sustained growth within a competitive landscape.

AXNX Intrinsic Value
33.87 USD
Overvaluation 52%
Intrinsic Value
Price

See Also

What is Axonics Inc's Depreciation & Amortization?
Depreciation & Amortization
-9m USD

Based on the financial report for Sep 30, 2024, Axonics Inc's Depreciation & Amortization amounts to -9m USD.

What is Axonics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
-21%

Over the last year, the Depreciation & Amortization growth was 1%. The average annual Depreciation & Amortization growth rates for Axonics Inc have been -21% over the past three years .

Back to Top